Intravenous Iron Drugs Market by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global intravenous iron drugs market size is anticipated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing geriatric population, increasing people with chronic diseases and patients undergoing dialysis.
Iron is a crucial mineral of the body. It is a critical element of hemoglobin which delivers oxygen throughout your body. Iron is also required for heme synthesis, energy metabolism, neurotransmitter creation, myoglobin development, collagen development, and immune system function. Iron deficiency is one of the leading causes of iron deficiency anemia (IDA), which is linked to an increased risk of morbidity and death. Oral and intravenous iron supplements are available. Oral iron supplements are slower to intravenous iron preparations because they result in a greater and faster increase in iron and hemoglobin levels. Gastrointestinal side effects, low adherence, low gastrointestinal absorption, and noncompliance are among drawbacks of oral supplements.
Intravenous iron infusion is a method of delivering iron to your blood rapidly by inserting a tiny tube into a vein in your arm and administering a liquid solution containing iron. Doctors typically prescribe iron infusions to treat iron deficiency anemia. Dietary modifications and iron supplementation in tablet form are usually used to treat iron deficiency anemia. Doctors may, however, suggest iron infusions in specific circumstances. The demand for iron in a pregnant woman increases as her fetus grows. The mother's iron levels may decline as the fetus takes iron from her body, leading in anemia. As a result, doctors occasionally prescribe iron infusions for pregnant women. An iron infusion is a rapid technique to boost your body's iron levels. It is a faster solution than supplements or dietary adjustments. This can be extremely beneficial in cases of severe anemia. An iron infusion has physical benefits such as increased energy and better breathing. These advantages should begin to manifest a few weeks following your final infusion therapy. The amount of time these advantages persist is determined on the cause of your iron deficiency anemia and if any additional treatments are taken to raise your iron levels. For example, regular blood loss, such as through menstruation, can result in a continual reduction in iron levels. The effects of an iron infusion might last anywhere from a few months to a few years, depending on condition. Additional iron-increasing treatments, like as supplementation and dietary adjustments, may be recommended by your doctor to extend the effects.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing incidence of iron deficiency, growing chronic kidney disorders patients undergoing dialysis and increasing diabetic patients around the world are factors driving the market growth during the forecast period.
- Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology conditions, and accurate, quick, and convenient access to IV iron doses are projected to boost the market growth during the forecast period.
- Increased initiatives by public and private institutes for spreading the awareness regarding the need for safe levels of iron in pregnant women is expected to fuel the market growth in the coming years.
- Growing awareness among the people regarding healthcare and personal care is estimated to boost the market growth during the forecast period.
- Stringent drug approval framework is projected to hamper the market growth during the forecast period.
- Side-effects associated with intravenous iron infusion is anticipated to impede the market growth during the forecast period.
- High cost of treatment and not suitable for first trimester of pregnancy are major challenges that can restrict the market growth during the forecast period.
- Increased emphasis on R&D for novel product development and increasing need for preventing anemia in pregnant women are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global intravenous iron drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Intravenous Iron Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Allergan, Inc.; Daiichi Sankyo Company, Ltd.; Rockwell Medical Technologies, Inc.; AMAG Pharmaceuticals. Inc.; Sanofi; Fresenius Medical Care AG & Co.; Vifor Pharma Management Ltd.; Pharmacosmos A/S; Shield Therapeutics Plc; American Regent. Inc. |
Market Segment Insights
Ferric carboxymaltose segment is expected to account for a key share of the market
Based on product, the intravenous iron drugs market is segmented into iron dextran, iron sucrose, ferric carboxymaltose, and others. The ferric carboxymaltose segment is expected to account for a key share of the market during the forecast period due to increasing use in drug development, improved performance, and lower cost.
On the other hand, the iron sucrose segment is anticipated to expand at a rapid pace during the forecast period due to increased number of product launches such as diafer and feraccru.
Chronic kidney disease segment is expected to constitute a key share of the market
Based on application, the intravenous iron drugs market is segmented into chronic kidney disease, inflammatory bowel disease, cancer, and other. The chronic kidney disease segment is expected to constitute a key share of the market during the forecast period due to increasing incidence, a growing geriatric population, and a shift towards a sedentary lifestyle. Intravenous medicines are preferred over oral tablets in several situations of iron deficiency. These IV iron drugs are used when the body cannot absorb dietary iron, when a quick rise in hemoglobin is required, or when there is underlying inflammation, such as in inflammatory bowel disease or Chronic Kidney Disorder patients.
On the other hand, the cancer segment is anticipated to expand at a rapid pace during the forecast period owing to its increasing prevalence and increasing oncology cohort.
North America is anticipated to dominate the market
On the basis of regions, the intravenous iron drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing use of intravenous iron medications in cancer research, the use of low-cost & compact intravenous iron medications in clinical diagnostics, and the development of research lab infrastructure.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increasing government investment in the biotechnology and biopharmaceutical industries, the development of innovative biologics, vaccines, and medications, the expansion of medical treatment for infectious and chronic illnesses, and a large number of investment possibilities in these markets. The growth of the region can be highly attributed to countries such as Japan, China, South Korea, and India.
Segments
Segments Covered in the ReportThe global intravenous iron drugs market has been segmented on the basis of
Product
- Iron Dextran
- Iron Sucrose
- Ferric Carboxymaltose
- Others
- Chronic Kidney Disease
- Inflammatory Bowel Disease
- Cancer
- Other Diseases
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Allergan, Inc.
- Daiichi Sankyo Company, Ltd.
- Rockwell Medical Technologies, Inc.
- AMAG Pharmaceuticals. Inc.
- Sanofi
- Fresenius Medical Care AG & Co.
- Vifor Pharma Management Ltd.
- Pharmacosmos A/S
- Shield Therapeutics Plc.
- American Regent. Inc.
Competitive Landscape
Key players competing in the intravenous iron drugs market are Allergan, Inc.; Daiichi Sankyo Company, Ltd.; Rockwell Medical Technologies, Inc.; AMAG Pharmaceuticals. Inc.; Sanofi; Fresenius Medical Care AG & Co.; Vifor Pharma Management Ltd.; Pharmacosmos A/S; Shield Therapeutics Plc; American Regent. Inc.
Emergence of new entrants and the existence of well-established companies, the global intravenous iron drugs market is extremely competitive. Some of the key business strategies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase companies market shares.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intravenous Iron Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Intravenous Iron Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Intravenous Iron Drugs Market - Supply Chain
4.5. Global Intravenous Iron Drugs Market Forecast
4.5.1. Intravenous Iron Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Intravenous Iron Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Intravenous Iron Drugs Market Absolute $ Opportunity
5. Global Intravenous Iron Drugs Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Intravenous Iron Drugs Market Size and Volume Forecast by Types
5.3.1. Iron Dextran
5.3.2. Iron Sucrose
5.3.3. Ferric Carboxymaltose
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Intravenous Iron Drugs Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Intravenous Iron Drugs Market Size and Volume Forecast by Applications
6.3.1. Chronic Kidney Disease
6.3.2. Inflammatory Bowel Disease
6.3.3. Cancer
6.3.4. Other Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Intravenous Iron Drugs Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Intravenous Iron Drugs Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Intravenous Iron Drugs Demand Share Forecast, 2019-2026
8. North America Intravenous Iron Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Intravenous Iron Drugs Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Intravenous Iron Drugs Market Size and Volume Forecast by Types
8.4.1. Iron Dextran
8.4.2. Iron Sucrose
8.4.3. Ferric Carboxymaltose
8.4.4. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
8.7.1. Chronic Kidney Disease
8.7.2. Inflammatory Bowel Disease
8.7.3. Cancer
8.7.4. Other Diseases
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
9. Latin America Intravenous Iron Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Types
9.4.1. Iron Dextran
9.4.2. Iron Sucrose
9.4.3. Ferric Carboxymaltose
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
9.7.1. Chronic Kidney Disease
9.7.2. Inflammatory Bowel Disease
9.7.3. Cancer
9.7.4. Other Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
10. Europe Intravenous Iron Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Types
10.4.1. Iron Dextran
10.4.2. Iron Sucrose
10.4.3. Ferric Carboxymaltose
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Applications
10.7.1. Chronic Kidney Disease
10.7.2. Inflammatory Bowel Disease
10.7.3. Cancer
10.7.4. Other Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Intravenous Iron Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Types
11.4.1. Iron Dextran
11.4.2. Iron Sucrose
11.4.3. Ferric Carboxymaltose
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Applications
11.7.1. Chronic Kidney Disease
11.7.2. Inflammatory Bowel Disease
11.7.3. Cancer
11.7.4. Other Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Intravenous Iron Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Intravenous Iron Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Types
12.4.1. Iron Dextran
12.4.2. Iron Sucrose
12.4.3. Ferric Carboxymaltose
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Applications
12.7.1. Chronic Kidney Disease
12.7.2. Inflammatory Bowel Disease
12.7.3. Cancer
12.7.4. Other Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Intravenous Iron Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Intravenous Iron Drugs Market: Market Share Analysis
13.2. Intravenous Iron Drugs Distributors and Customers
13.3. Intravenous Iron Drugs Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Allergan, Inc.
13.4.2. Daiichi Sankyo Company, Ltd.
13.4.3. Rockwell Medical Technologies, Inc.
13.4.4. AMAG Pharmaceuticals. Inc.
13.4.5. Sanofi
13.4.6. Fresenius Medical Care AG & Co.
13.4.7. Vifor Pharma Management Ltd.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intravenous Iron Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Intravenous Iron Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Intravenous Iron Drugs Market - Supply Chain
4.5. Global Intravenous Iron Drugs Market Forecast
4.5.1. Intravenous Iron Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Intravenous Iron Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Intravenous Iron Drugs Market Absolute $ Opportunity
5. Global Intravenous Iron Drugs Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Intravenous Iron Drugs Market Size and Volume Forecast by Types
5.3.1. Iron Dextran
5.3.2. Iron Sucrose
5.3.3. Ferric Carboxymaltose
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Intravenous Iron Drugs Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Intravenous Iron Drugs Market Size and Volume Forecast by Applications
6.3.1. Chronic Kidney Disease
6.3.2. Inflammatory Bowel Disease
6.3.3. Cancer
6.3.4. Other Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Intravenous Iron Drugs Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Intravenous Iron Drugs Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Intravenous Iron Drugs Demand Share Forecast, 2019-2026
8. North America Intravenous Iron Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Intravenous Iron Drugs Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Intravenous Iron Drugs Market Size and Volume Forecast by Types
8.4.1. Iron Dextran
8.4.2. Iron Sucrose
8.4.3. Ferric Carboxymaltose
8.4.4. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
8.7.1. Chronic Kidney Disease
8.7.2. Inflammatory Bowel Disease
8.7.3. Cancer
8.7.4. Other Diseases
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
9. Latin America Intravenous Iron Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Types
9.4.1. Iron Dextran
9.4.2. Iron Sucrose
9.4.3. Ferric Carboxymaltose
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
9.7.1. Chronic Kidney Disease
9.7.2. Inflammatory Bowel Disease
9.7.3. Cancer
9.7.4. Other Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
10. Europe Intravenous Iron Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Types
10.4.1. Iron Dextran
10.4.2. Iron Sucrose
10.4.3. Ferric Carboxymaltose
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Applications
10.7.1. Chronic Kidney Disease
10.7.2. Inflammatory Bowel Disease
10.7.3. Cancer
10.7.4. Other Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Intravenous Iron Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Types
11.4.1. Iron Dextran
11.4.2. Iron Sucrose
11.4.3. Ferric Carboxymaltose
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Applications
11.7.1. Chronic Kidney Disease
11.7.2. Inflammatory Bowel Disease
11.7.3. Cancer
11.7.4. Other Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Intravenous Iron Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Intravenous Iron Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Types
12.4.1. Iron Dextran
12.4.2. Iron Sucrose
12.4.3. Ferric Carboxymaltose
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Applications
12.7.1. Chronic Kidney Disease
12.7.2. Inflammatory Bowel Disease
12.7.3. Cancer
12.7.4. Other Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Intravenous Iron Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Intravenous Iron Drugs Market: Market Share Analysis
13.2. Intravenous Iron Drugs Distributors and Customers
13.3. Intravenous Iron Drugs Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Allergan, Inc.
13.4.2. Daiichi Sankyo Company, Ltd.
13.4.3. Rockwell Medical Technologies, Inc.
13.4.4. AMAG Pharmaceuticals. Inc.
13.4.5. Sanofi
13.4.6. Fresenius Medical Care AG & Co.
13.4.7. Vifor Pharma Management Ltd.
Segments Covered in the Report
The global intravenous iron drugs market has been segmented on the basis of
Product
The global intravenous iron drugs market has been segmented on the basis of
Product
- Iron Dextran
- Iron Sucrose
- Ferric Carboxymaltose
- Others
- Chronic Kidney Disease
- Inflammatory Bowel Disease
- Cancer
- Other Diseases
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Allergan, Inc.
- Daiichi Sankyo Company, Ltd.
- Rockwell Medical Technologies, Inc.
- AMAG Pharmaceuticals. Inc.
- Sanofi
- Fresenius Medical Care AG & Co.
- Vifor Pharma Management Ltd.
- Pharmacosmos A/S
- Shield Therapeutics Plc.
- American Regent. Inc.
Key players competing in the intravenous iron drugs market are Allergan, Inc.; Daiichi Sankyo Company, Ltd.; Rockwell Medical Technologies, Inc.; AMAG Pharmaceuticals. Inc.; Sanofi; Fresenius Medical Care AG & Co.; Vifor Pharma Management Ltd.; Pharmacosmos A/S; Shield Therapeutics Plc; American Regent. Inc.
Emergence of new entrants and the existence of well-established companies, the global intravenous iron drugs market is extremely competitive. Some of the key business strategies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase companies market shares.
Our Clients
Related Reports
Some other reports from this category!
